Latest news - Novo Nordisk
2024年12月15日 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and …
4 天之前 · Bad news for Novo Nordisk (NVO 4.37%) Friday was good news for Eli Lilly (LLY 3.71%) and Viking Therapeutics (VKTX 0.17%), its two main rivals in the field of weight loss drugs.This morning, Novo ...
FDA approves generic version of Novo Nordisk's GLP-1 ... - NBC News
1 天前 · The Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug Victoza, which is currently in shortage in the country.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
4 天之前 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk A/S: CagriSema demonstrates superior weight
4 天之前 · Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and ...
Novo Nordisk shares slump as weight-loss drug trial data …
4 天之前 · Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
2024年11月6日 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
News Details - novonordisk.com
2024年10月21日 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial.
Company announcements & press releases - Novo Nordisk
Press releases are intended for the media. Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
Novo Nordisk shares plunge on the back of disappointing
2 天之前 · Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday.